Lisata Therapeutics (LSTA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright remains neutral on the stock and has a $15.00 price target.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Lisata Therapeutics’ promising drug candidate, LSTA1. His optimism is primarily fueled by a case report showing a complete response in a patient with advanced gastroesophageal cancer who was treated with LSTA1 in combination with the standard of care. Pantginis is encouraged by this early signal and the potential of LSTA1 to effectively penetrate tumors and enhance the uptake of anti-cancer drugs, which could improve treatment outcomes across various advanced solid tumors. He believes that the drug’s mode of action and ongoing clinical trials in different cancer types signify a strong future potential for Lisata Therapeutics.
Moreover, Pantginis’ rating is boosted by the recent completion of enrollment ahead of schedule for the Phase 2b ASCEND study, which evaluates LSTA1 in metastatic pancreatic ductal adenocarcinoma patients. This development suggests that the study’s timelines might be accelerated, providing earlier data readouts that could lead to conditional approvals and the advancement to a Phase 3 program. The analyst’s confidence is also reflected in the diverse clinical trials and responses that LSTA1 is garnering, which supports his positive outlook on the stock.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Lisata Therapeutics (LSTA) Company Description:
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Read More on LSTA:
- Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
- Lisata Therapeutics announces completion of enrollment in Phase 2b ASCEND trial
- Lisata Therapeutics to Present at NobleCon19 Investor Conference
